(ATDN) Treatment Briefs: 3TC Expanded Access Program Changes Again

(ATDN) Treatment Briefs: 3TC Expanded Access Program Changes Again

Treatment Review; August 1995

The experimental anti-HIV drug 3TC has been available through an expanded access program for some time now. 3TC is a nucleoside analog like the other approved anti-HIV drugs AZT, ddI, ddC and d4T. Studies seem to indicate that it has less side effects than the approved drugs, and works particularly well in combination with other anti- HIV drugs.Doctors have been able to obtain the drug for their patients directly from the company that makes it, Glaxo Wellcome. Due to problems with drug supply, the entry criteria for this program were recently restricted so that only people with under 100 T cells could be enrolled, and a maximum of 350 people could enter the program each week. Glaxo Wellcome has now announced that as of August 15th, 1995 people with less than 300 T cells can ask their doctor to enroll them in the program by calling 1.800.248.9757. The number of people that can be enrolled each week has also been increased to 650.

950801
ATR1909

Always watch for outdated information. This article first appeard in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Copyright © 1995 - AIDS Treatment Data Network. If you want to copy, reproduce or excerpt this information, please give us a call at (800) 734-7104. This helps up to keep track of where and how this information is being used. You can also Email us at network@atdn.org http://206.179.124.69/network/index.html

This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1995. AEGIS.